33 related articles for article (PubMed ID: 38557285)
1. Pseudo-Richter Transformation of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma After Temporary Acalabrutinib Interruption.
Shi M; Yuan J
Mayo Clin Proc; 2024 Jun; 99(6):867-868. PubMed ID: 38691072
[No Abstract] [Full Text] [Related]
2. Acalabrutinib plus venetoclax and rituximab in treatment-naive mantle cell lymphoma: 2-year safety and efficacy analysis.
Wang ML; Robak T; Maddocks KJ; Phillips TJ; Smith SD; Gallinson D; Calvo R; Wun CC; Munugalavadla V; Jurczak W
Blood Adv; 2024 May; ():. PubMed ID: 38781315
[TBL] [Abstract][Full Text] [Related]
3. Safety and antitumor activity of acalabrutinib for relapsed/refractory B-cell malignancies: A Japanese phase I study.
Izutsu K; Ando K; Ennishi D; Shibayama H; Suzumiya J; Yamamoto K; Ichikawa S; Kato K; Kumagai K; Patel P; Iizumi S; Hayashi N; Kawasumi H; Murayama K; Nagai H
Cancer Sci; 2021 Jun; 112(6):2405-2415. PubMed ID: 33728735
[TBL] [Abstract][Full Text] [Related]
4. Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma.
Telford C; Kabadi SM; Abhyankar S; Song J; Signorovitch J; Zhao J; Yao Z
Clin Ther; 2019 Nov; 41(11):2357-2379.e1. PubMed ID: 31699438
[TBL] [Abstract][Full Text] [Related]
5. Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results.
Byrd JC; Wierda WG; Schuh A; Devereux S; Chaves JM; Brown JR; Hillmen P; Martin P; Awan FT; Stephens DM; Ghia P; Barrientos J; Pagel JM; Woyach JA; Burke K; Covey T; Gulrajani M; Hamdy A; Izumi R; Frigault MM; Patel P; Rothbaum W; Wang MH; O'Brien S; Furman RR
Blood; 2020 Apr; 135(15):1204-1213. PubMed ID: 31876911
[TBL] [Abstract][Full Text] [Related]
6. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial.
Wang M; Rule S; Zinzani PL; Goy A; Casasnovas O; Smith SD; Damaj G; Doorduijn J; Lamy T; Morschhauser F; Panizo C; Shah B; Davies A; Eek R; Dupuis J; Jacobsen E; Kater AP; Le Gouill S; Oberic L; Robak T; Covey T; Dua R; Hamdy A; Huang X; Izumi R; Patel P; Rothbaum W; Slatter JG; Jurczak W
Lancet; 2018 Feb; 391(10121):659-667. PubMed ID: 29241979
[TBL] [Abstract][Full Text] [Related]
7. Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib.
Awan FT; Schuh A; Brown JR; Furman RR; Pagel JM; Hillmen P; Stephens DM; Woyach J; Bibikova E; Charuworn P; Frigault MM; Hamdy A; Izumi R; Linghu B; Patel P; Wang MH; Byrd JC
Blood Adv; 2019 May; 3(9):1553-1562. PubMed ID: 31088809
[TBL] [Abstract][Full Text] [Related]
8. Phase 1/2 multicenter trial of acalabrutinib in Chinese patients with relapsed/refractory mantle cell lymphoma.
Song Y; Li J; Zhou K; Ke X; Cai Z; Zhang H; Yao T; Xia Z; Wang Y; Lai P; Liu X; Zhu J
Leuk Lymphoma; 2024 May; 65(5):647-652. PubMed ID: 38557285
[TBL] [Abstract][Full Text] [Related]
9. Acalabrutinib for adults with mantle cell lymphoma.
Jurczak W; Długosz-Danecka M; Wang M
Expert Rev Clin Pharmacol; 2019 Mar; 12(3):179-187. PubMed ID: 30638402
[TBL] [Abstract][Full Text] [Related]
10. Acalabrutinib and its use in treatment of chronic lymphocytic leukemia.
Khan Y; O'Brien S
Future Oncol; 2019 Feb; 15(6):579-589. PubMed ID: 30381956
[TBL] [Abstract][Full Text] [Related]
11. Use of acalabrutinib in patients with mantle cell lymphoma.
Awan FT; Jurczak W
Expert Rev Hematol; 2018 Jun; 11(6):495-502. PubMed ID: 29737219
[TBL] [Abstract][Full Text] [Related]
12. Incorporating acalabrutinib, a selective next-generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies.
Danilov AV; Persky DO
Br J Haematol; 2021 Apr; 193(1):15-25. PubMed ID: 33216986
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
